Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 5/20 | 0.36 |
| ▸ | CA2 | P00918 | 3/20 | 0.36 |
| ▸ | CA9 | Q16790 | 3/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | TACR1 | P25103 | 2/20 | 0.35 |
| ▸ | KLK7 | P49862 | 1/20 | 0.35 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.35 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2385557 | 1.00 | CA1 (0.36) | CA1CA2CA9CYP3A4ALOX15 | |
| SCHEMBL2385183 | 1.00 | CA1 (0.36) | CA1CA2CA9CYP3A4ALOX15 | |
| SCHEMBL2385181 | 1.00 | CA1 (0.36) | CA1CA2CA9CYP3A4ALOX15 | |
| SCHEMBL2385554 | 1.00 | CA1 (0.36) | CA1CA2CA9CYP3A4ALOX15 | |
| SCHEMBL2385178 | 1.00 | CA1 (0.36) | CA1CA2CA9CYP3A4ALOX15 | |
| SCHEMBL2385217 | 0.80 | CA1 (0.37) | CA1CA2CA9SLC1A1 | |
| SCHEMBL2385224 | 0.80 | CA1 (0.37) | CA1CA2CA9SLC1A1 | |
| SCHEMBL2384373 | 0.78 | NAAA (0.38) | CA1CA2CA9POLBHTT | |
| SCHEMBL2385647 | 0.78 | NAAA (0.36) | CA1CA2CA9POLB | |
| SCHEMBL2384378 | 0.78 | NAAA (0.38) | CA1CA2CA9POLBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8293715-B2 | 10a-Azalide compound crosslinked at 10a- and 12-positions | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-10-23 | — | — | US | disclosed |
| US-20110237784-A1 | 10A-AZALIDE COMPOUND CROSSLINKED AT 10A- AND 12-POSITIONS | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-09-29 | — | — | US | disclosed |
| EP-2177526-A1 | 10A-AZALIDE COMPOUND CROSSLINKED AT POSITION-10A AND POSITION-12 | Taisho Pharmaceutical Co. Ltd. (JP) | 2010-04-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237784-A1 | 10A-AZALIDE COMPOUND CROSSLINKED AT 10A- AND 12-POSITIONS | DCLRE1A, AZI2, CHD9 | CA1 4385/4885CA2 4764/4885CA9 767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.